Comparison of eligibility criteria and baseline characteristics between the patient populations of e...
Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2
About this item
Full title
Author / Creator
Publisher
Hoboken: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Background
evoke and evoke+ are phase 3, randomized, placebo‐controlled trials currently investigating the glucagon‐like peptide‐1 receptor agonist semaglutide as disease‐modifying therapy (DMT) in persons with early Alzheimer’s disease (AD). How the evoke and evoke+ trial populations compare with other phase 3 programs for DMTs in early AD has...
Alternative Titles
Full title
Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713343
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11713343
Other Identifiers
ISSN
1552-5260
E-ISSN
1552-5279
DOI
10.1002/alz.083684
